TELA
$0.80
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy.
Recent News
Astrana Health, Inc. (ASTH) Q4 Earnings and Revenues Surpass Estimates
Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of +252.25% and +2.89%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
Anika (ANIK) delivered earnings and revenue surprises of +1,450.00% and +6.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio Inc (TELA) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic Expansions ...
Despite achieving a new revenue milestone, TELA Bio Inc (TELA) faces profitability hurdles and revises future growth expectations.
TELA Bio, Inc. (TELA) Reports Q3 Loss, Misses Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -11.76% and -5.53%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of +17.65% and -17.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?